Shares of Arkema SA (OTCMKTS:ARKAY - Get Free Report) have received an average recommendation of "Reduce" from the eight analysts that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company.
A number of analysts recently commented on the company. Zacks Research lowered Arkema from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 6th. The Goldman Sachs Group raised shares of Arkema from a "hold" rating to a "buy" rating in a research note on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft cut shares of Arkema from a "buy" rating to a "hold" rating in a research report on Monday, November 24th. Finally, Kepler Capital Markets downgraded shares of Arkema from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 27th.
Get Our Latest Research Report on ARKAY
Arkema Price Performance
ARKAY opened at $59.02 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.07 and a quick ratio of 2.26. The stock's 50 day simple moving average is $65.70 and its 200 day simple moving average is $63.18. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 67.84, a PEG ratio of 1.52 and a beta of 0.87. Arkema has a 1 year low of $56.28 and a 1 year high of $84.62.
Arkema Company Profile
(
Get Free Report)
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total's chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema's operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arkema, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arkema wasn't on the list.
While Arkema currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.